Literature DB >> 3562060

Variants with reduced virulence derived from Leishmania major after mutagen treatment.

M Marchand, S Daoud, R G Titus, J Louis, T Boon.   

Abstract

After several in vitro treatments of a virulent population of Leishmania major with the mutagen, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), five clones (vir-) were obtained that did not produce cutaneous lesions after subcutaneous injection of 10(6) promastigotes. All the control clones (vir+) obtained from the non-mutagenized parasite population produced progressive cutaneous lesions with as few as 10(3) parasites. Late lesions were observed occasionally after injection of 10(7) vir- parasites. These late lesions appeared to result from the selection of virulent revertants, since parasites isolated from these lesions produced progressive lesions in BALB/c mice almost as readily as the control parasites. Two vir- clones, one vir+ clone and one revertant clone were examined for survival in BALB/c macrophages in vitro. All clones were taken up by the macrophages and transformed into amastigotes. However, vir- clones failed to multiply inside the macrophages. A vir- clone was found to protect mice against a subsequent challenge with vir+ parasites.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3562060     DOI: 10.1111/j.1365-3024.1987.tb00490.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  15 in total

1.  Priming of a beta-galactosidase (beta-GAL)-specific type 1 response in BALB/c mice infected with beta-GAL-transfected Leishmania major.

Authors:  H R Chakkalath; A A Siddiqui; A H Shankar; D E Dobson; S M Beverley; R G Titus
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  An in vitro model for infection with Leishmania major that mimics the immune response in mice.

Authors:  M B Soares; J R David; R G Titus
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major.

Authors:  G F Späth; L Epstein; B Leader; S M Singer; H A Avila; S J Turco; S M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

4.  Development of a safe live Leishmania vaccine line by gene replacement.

Authors:  R G Titus; F J Gueiros-Filho; L A de Freitas; S M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

5.  Selection against the dihydrofolate reductase-thymidylate synthase (DHFR-TS) locus as a probe of genetic alterations in Leishmania major.

Authors:  F J Gueiros-Filho; S M Beverley
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

6.  Proteophosphoglycan confers resistance of Leishmania major to midgut digestive enzymes induced by blood feeding in vector sand flies.

Authors:  Nagila Secundino; Nicola Kimblin; Nathan C Peters; Phillip Lawyer; Althea A Capul; Stephen M Beverley; Salvatore J Turco; David Sacks
Journal:  Cell Microbiol       Date:  2010-01-20       Impact factor: 3.715

7.  The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts.

Authors:  Gerald F Späth; L A Garraway; Salvatore J Turco; Stephen M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

Review 8.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

9.  Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo.

Authors:  C M Theodos; L Povinelli; R Molina; B Sherry; R G Titus
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

10.  Leishmania major glycosylation mutants require phosphoglycans (lpg2-) but not lipophosphoglycan (lpg1-) for survival in permissive sand fly vectors.

Authors:  Anna Svárovská; Thomas H Ant; Veronika Seblová; Lucie Jecná; Stephen M Beverley; Petr Volf
Journal:  PLoS Negl Trop Dis       Date:  2010-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.